In subjects with T2DM, weekly administration of tirzepatide at doses of 5 mg, 10 mg, or 15 mg was associated with greater weight loss compared to placebo ( 6.3 kg, 8.4 kg, and 9.4 kg, respectively), and 1.7 kg, 4.8 kg, and 7.2 kg greater weight loss compared to selective GLP-1 receptor agonists, demonstrating a dose-dependent effect sustained for up to 2 years [48]
15 Dose adjustment does not appear to be necessary in patients with hepatic impairment, although exenatide has not been specifically studied in this population
Kuznetsova, V
For your clinic, this impacts: Your service menu Treatment descriptions Consent forms Marketing materials If you say a treatment is "FDA-approved" when it isn't, or hint at benefits the data doesn't back, you risk regulatory trouble
It also promotes synthesis of elastin, glycosaminoglycans, and other matrix components that give tissues their characteristic properties